Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 1;64(1):7-15.
doi: 10.2169/internalmedicine.2867-23. Epub 2023 Nov 13.

Management of Chronic Constipation: A Comprehensive Review

Affiliations
Review

Management of Chronic Constipation: A Comprehensive Review

Mariko Hojo et al. Intern Med. .

Abstract

Traditionally, the treatment of chronic constipation has focused on lifestyle modification, dietary guidance and therapy, and osmotic and stimulant laxatives. Recently, several drugs with new mechanisms of action have been introduced as treatments for chronic constipation. In Japan, polyethylene glycol and lactulose can now be administered under insurance coverage. The number of treatment options for constipation has increased dramatically. First, lifestyle modifications and dietary therapies must be implemented. If constipation does not improve sufficiently, specialized functional tests are performed to diagnose physiological subgroups. If functional tests are not available, patients are classified as having the "decreased frequency of defecation" type or the "difficult defecation" type based on the patient's symptoms, with treatment applied according to each type. Medical therapy includes osmotic laxatives, secretagogues, bile acid transporter inhibitors, probiotics, prokinetics, and Kampo medicines. The temporary use of stimulant laxatives, suppositories, enemas, and digital evacuation is also recommended. The usefulness of biofeedback is yet to be determined.

Keywords: elobixibat; linaclotide; lubiprostone; osmotic laxatives; stimulant laxatives.

PubMed Disclaimer

Conflict of interest statement

Akihito Nagahara: Honoraria, Astellas Pharma, EA Pharma, Tsumura and Viatris.

Similar articles

Cited by

References

    1. The Japanese Gastroenterological Association . In: Evidence-Based Clinical Practice Guidelines for Chronic Constipation. Nankodo, Tokyo, 2023. (in Japanese).
    1. Mearin F, Lacy BE, Chang L, et al. . Bowel disorders. Gastroenterology 150: 1393-1407, 2016. - PubMed
    1. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology 158: 1262-1273.e3, 2020. - PubMed
    1. Schmidt FMQ, de Gouveia Santos VLC. Prevalence of constipation in the general adult population: an integrative review. J Wound Ostomy Continence Nurs 41: 70-76; quiz E1-E2, 2014. - PubMed
    1. Ruszkowski J, Heleniak Z, Król E, et al. . Constipation and the quality of life in conservatively treated chronic kidney disease patients: a cross-sectional study. Int J Med Sci 17: 2954-2963, 2020. - PMC - PubMed